OLEMA PHARMACEUTICALS, INC. Net Income (Loss) Available to Common Stockholders, Basic
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$71.10 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2022-02-28
- OLEMA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-12-31 was -$21.64M.
- OLEMA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-09-30 was -$17.71M.
- OLEMA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-12-31 was -$10.13M.
- OLEMA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-09-30 was -$9.71M.
- OLEMA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2021 was -$71.10M.
- OLEMA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$23.99M.
- OLEMA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2019 was -$4.32M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$21.64M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$39.35M derived: sum of 2 quarters · filed 2022-02-28 | -$71.10M 10-K · filed 2022-02-28 | |
| 2021-09-30 | -$17.71M 10-Q · filed 2021-11-10 | -$49.46M 10-Q · filed 2021-11-10 | ||
| 2020-12-31 | -$10.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$19.84M derived: sum of 2 quarters · filed 2022-02-28 | -$23.99M 10-K · filed 2022-02-28 | |
| 2020-09-30 | -$9.71M 10-Q · filed 2021-11-10 | -$13.86M 10-Q · filed 2021-11-10 | ||
| 2019-12-31 | -$4.32M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |